AR101735A1 - Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro) - Google Patents
Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro)Info
- Publication number
- AR101735A1 AR101735A1 ARP150102797A ARP150102797A AR101735A1 AR 101735 A1 AR101735 A1 AR 101735A1 AR P150102797 A ARP150102797 A AR P150102797A AR P150102797 A ARP150102797 A AR P150102797A AR 101735 A1 AR101735 A1 AR 101735A1
- Authority
- AR
- Argentina
- Prior art keywords
- chain variable
- variable region
- seq
- heavy chain
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicación 1: Un anticuerpo anti-BDNF aislado, o una porción de unión a antígeno del mismo, caracterizado porque el anticuerpo: (a) se une a BDNF humano, y (b) compite por unión a BDNF humano con, y/o se une al mismo epítopo en BDNF humano como, un anticuerpo de referencia que comprende: (i) una región variable de cadena pesada que comprende la secuencia de aminoácido de SEC ID Nº 14 y una región variable de cadena ligera que comprende la secuencia de aminoácido de SEC ID Nº 16; o (ii) una región variable de cadena pesada que comprende la secuencia de aminoácido de SEC ID Nº 4 y una región variable de cadena ligera que comprende la secuencia de aminoácido de SEC ID Nº 6; o (iii) una región variable de cadena pesada que comprende la secuencia de aminoácido de SEC ID Nº 18 y una región variable de cadena ligera que comprende la secuencia de aminoácido de SEC ID Nº 20; o (iv) una región variable de cadena pesada que comprende la secuencia de aminoácido de SEC ID Nº 22 y una región variable de cadena ligera que comprende la secuencia de aminoácido de SEC ID Nº 24. Reivindicación 24: Una molécula de ácido nucleico aislada de conformidad con la reivindicación 23, caracterizada porque codifica: (i) una región de cadena pesada que comprende la secuencia de región variable de cadena pesada SEC ID Nº 4 y/o una región de cadena ligera que comprende la región variable de cadena ligera de SEC ID Nº 6, o (ii) una región de cadena pesada que comprende la secuencia de región variable de cadena pesada de SEC ID Nº 14 y/o una región de cadena ligera que comprende la secuencia de región variable de cadena ligera de SEC ID Nº 16, o (iii) una región de cadena pesada que comprende la secuencia de región variable de cadena pesada de SEC ID Nº 18 y/o una región de cadena ligera que comprende la secuencia de región variable de cadena ligera de SEC ID Nº 20, o (iv) una región de cadena pesada que comprende la secuencia de región variable de cadena pesada de SEC ID Nº 22 y/o una región de cadena ligera que comprende la secuencia de región variable de cadena ligera de SEC ID Nº 24. Reivindicación 28: Un método de producir un anticuerpo anti-BDNF, caracterizado porque comprende cultivar la célula huésped de conformidad con la reivindicación 27 bajo condiciones que resultan en expresión y/o producción del anticuerpo, y aislar el anticuerpo de la célula huésped o cultivo. Reivindicación 37: Un método para tratar y/o prevenir dolor en un sujeto, caracterizado porque comprende administrar una cantidad efectiva del anticuerpo o porción de unión a antígeno del mismo, de conformidad con cualquiera de las reivindicaciones 1 a 20, inmunoconjugado de conformidad con la reivindicación 21, composición farmacéutica de conformidad con la reivindicación 22.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462044579P | 2014-09-02 | 2014-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR101735A1 true AR101735A1 (es) | 2017-01-11 |
Family
ID=54207627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150102797A AR101735A1 (es) | 2014-09-02 | 2015-09-01 | Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro) |
Country Status (5)
Country | Link |
---|---|
US (1) | US20160207991A1 (es) |
AR (1) | AR101735A1 (es) |
CA (1) | CA2902253A1 (es) |
TW (1) | TW201615662A (es) |
WO (1) | WO2016034968A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110545842A (zh) * | 2017-01-20 | 2019-12-06 | 加利福尼亚大学董事会 | 使用抗emp2抗体和pd-1/pdl-1途径拮抗剂组合疗法治疗癌症 |
MX2020002351A (es) * | 2017-08-28 | 2021-02-26 | Shanghai Yile Biotechnology Co Ltd | Polipeptido y anticuerpo unido al polipeptido. |
US20210340265A1 (en) * | 2018-11-02 | 2021-11-04 | Unm Rainforest Innovations | Therapeutic antibody fragments, methods of making, and methods of use |
TW202045545A (zh) * | 2019-02-22 | 2020-12-16 | 美商安維塔生物科學股份有限公司 | 白蛋白結合抗體及其用途 |
US11692020B2 (en) | 2019-11-20 | 2023-07-04 | Anwita Biosciences, Inc. | Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications |
CN114891110A (zh) * | 2020-12-31 | 2022-08-12 | 中元汇吉生物技术股份有限公司 | 特异性结合人IgG4的蛋白及其应用 |
CN112851794B (zh) * | 2021-02-04 | 2023-05-23 | 苏州铂维生物科技有限公司 | 一种基于cd271的抗原表位及其应用 |
WO2023076959A1 (en) * | 2021-10-26 | 2023-05-04 | Monell Chemical Senses Center | Compositions and methods for diagnosing and treating parkinson's disease |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
US5037651A (en) | 1987-01-30 | 1991-08-06 | American Cyanamid Company | Dihydro derivatives of LL-E33288 antibiotics |
US5108912A (en) | 1987-01-30 | 1992-04-28 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5952329A (en) | 1996-01-23 | 1999-09-14 | The General Hospital Corporation | Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors |
WO1998021245A1 (de) * | 1996-11-08 | 1998-05-22 | Roche Diagnostics Gmbh | eOCHAFFINE ANTIKÖRPER GEGEN HUMAN-BDNF, VERFAHREN ZU IHRER HERSTELLUNG UND VERWENDUNG |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
AU3734900A (en) | 1999-03-09 | 2000-09-28 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
US7498029B2 (en) | 2001-05-01 | 2009-03-03 | The General Hospital Corporation | Photoimmunotherapies for cancer using combination therapies |
US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
CN101060863B (zh) * | 2004-10-22 | 2012-06-06 | 拉瓦勒大学 | 疼痛的治疗和预防中神经胶质细胞来源的bdnf的调节 |
WO2007088479A1 (en) * | 2006-02-02 | 2007-08-09 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkb antagonist |
US9512178B2 (en) * | 2012-07-11 | 2016-12-06 | Research Foundation For Mental Hygiene, Inc. | Neurogenic brain-derived neurotrophic factor peptides |
-
2015
- 2015-08-19 WO PCT/IB2015/056298 patent/WO2016034968A1/en active Application Filing
- 2015-08-28 CA CA2902253A patent/CA2902253A1/en not_active Abandoned
- 2015-09-01 TW TW104128848A patent/TW201615662A/zh unknown
- 2015-09-01 AR ARP150102797A patent/AR101735A1/es unknown
- 2015-09-01 US US14/842,422 patent/US20160207991A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2016034968A1 (en) | 2016-03-10 |
US20160207991A1 (en) | 2016-07-21 |
CA2902253A1 (en) | 2016-03-02 |
TW201615662A (zh) | 2016-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR101735A1 (es) | Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro) | |
CO2018012374A2 (es) | Moléculas de anticuerpo para el tratamiento del cáncer | |
UY38242A (es) | Anticuerpos anti-cd33, anticuerpos bioespecíficos anti- cd33/anti-cd3 y usos de éstos | |
EA201892548A1 (ru) | Антитела к альфа-синуклеину и их применение | |
CO2018012415A2 (es) | Proteínas de unión específica y usos de las mismas | |
BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
PE20190976A1 (es) | Anticuerpos de union a cd3 | |
BR112017003108A8 (pt) | Anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno | |
AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
EA201990293A1 (ru) | Мультиспецифичные антитела против cd40 и cd137 | |
PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
EA201590085A1 (ru) | Антитела анти-egfr и их применение | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
CO2019012329A2 (es) | Polipéptidos que antagonizan la señalización wnt en células tumorales | |
AR102239A1 (es) | Anticuerpos anti-ox40 humanizados y sus usos | |
BR112017008696A2 (pt) | métodos e composições para células exterminadoras naturais | |
AR115389A1 (es) | Anticuerpo antagonista de cd73 | |
AR085955A1 (es) | Proteinas de union al antigeno | |
EA201400625A1 (ru) | Антитела против pd-l1 и их применение | |
CL2022000664A1 (es) | Proteínas de fijación multiespecíficas para tratamiento contra el cáncer | |
EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
CO6460768A2 (es) | Anticuerpos específicos para dkk-1 y sus usos | |
AR093394A1 (es) | Anticuerpos especificos del factor de crecimiento b derivado de plaquetas (pdgf-b), composiciones y usos de estos | |
PE20191786A1 (es) | Anticuerpo monoclonal para pd-l1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |